THC, CBD and CBC: how cannabis produces these cannabinoids

Cannabis plants are chemical factories. In tiny glandular hairs called trichomes, a sequence of enzymes and simple building blocks come together to create cannabinoids like THC, CBD, and CBC — compounds that shape effects, aroma, and medical potential. Understanding how the plant synthesizes these molecules helps growers, researchers, and consumers make smarter choices about strains, cultivation, and product use.

This article walks through the biochemical pathways and biological machinery behind cannabinoid production, explains how enzymes determine whether a plant produces more THC, CBD, or CBC, and outlines how environmental factors and biotechnology can shift those outcomes. Expect a clear, science-backed guide that connects plant biology to what shows up in your vape pen or lab report.

From simple molecules to cannabinoid precursors: the chemical starting line

Cannabinoid synthesis begins with two basic metabolic streams inside the plant: one provides a short-chain isoprenoid (geranyl pyrophosphate, GPP), and the other supplies a polyketide-derived component (olivetolic acid). These two react to form the universal precursor for major cannabinoids, **cannabigerolic acid (CBGA)**.

• Geranyl pyrophosphate (GPP) — produced via the MEP pathway in plastids, GPP is a common building block also used to make terpenes.
• Olivetolic acid — formed through polyketide synthase activity, providing the phenolic backbone specific to cannabinoids.
• CBGA — the central branching point: once formed, CBGA can be turned into THCA, CBDA, or CBCA depending on which synthase enzyme acts on it.

This early chemistry explains why cannabinoids share structural similarities: they are all variations on the CBGA scaffold. The plant’s enzyme toolkit determines which branch of that chemical tree dominates.

Enzymes that decide the cannabinoid profile: THCA, CBDA, and CBCA synthases

Three primary synthase enzymes convert CBGA into the major acidic cannabinoids:

• THCA synthase — converts CBGA into tetrahydrocannabinolic acid (THCA), the precursor that becomes psychoactive THC after decarboxylation.
• CBDA synthase — converts CBGA into cannabidiolic acid (CBDA), which yields non-intoxicating CBD after activation.
• CBCA synthase — produces cannabichromenic acid (CBCA), the precursor to CBC.

Each synthase is encoded by distinct genes and varies among cannabis varieties. Some plants express a dominant form of THCA synthase and produce high levels of THCA, while others favor CBDA synthase and yield CBD-rich chemotypes. The relative expression, enzyme efficiency, and available CBGA pool together shape a strain’s cannabinoid fingerprint.

How small differences have big effects

Minor genetic changes in synthase genes or regulatory regions can shift enzyme activity. Variants that reduce THCA synthase activity while conserving CBDA synthase can turn a high-THC plant into a high-CBD cultivar across generations. Environmental factors that change CBGA availability — like nutrient status or light intensity — also tip the balance.

Decarboxylation: turning acidic cannabinoids into active molecules

Cannabinoids are produced by the plant primarily as carboxylic acids (THCA, CBDA, CBCA). These acidic forms are not the same as the familiar active molecules. Heat or time removes the carboxyl group in a process called decarboxylation, converting:

• THCA → THC (psychoactive)
• CBDA → CBD (non-intoxicating, therapeutic interest)
• CBCA → CBC (being studied for anti-inflammatory and other effects)

Smoking, vaping, or baking activates cannabinoids by applying heat. Some modern extraction and processing methods also deliberately decarboxylate material to produce ready-to-use THC or CBD oils. Decarboxylation is a critical step because it determines how the cannabinoids interact with the human endocannabinoid system.

Where cannabinoids are made: the role of glandular trichomes

Cannabinoid biosynthesis is concentrated in glandular trichomes — tiny, mushroom-shaped glands that coat flowers and, to a lesser extent, leaves. Trichomes serve multiple functions: they protect against herbivores and UV damage and act as micro-reactors where metabolic pathways are localized.

• Capitate-stalked trichomes are the primary production sites for cannabinoids and many terpenes.
• Trichome density and maturity influence total cannabinoid yield: more and larger trichomes generally mean higher concentrations.
• Environmental stresses often increase trichome activity, which can alter cannabinoid and terpene profiles.

Breeding for trichome traits or adjusting cultivation practices to boost trichome development is a common route for growers aiming to increase potency or tailor a product’s chemical profile.

Genes, environment, and cultivation: shaping the final cannabinoid mix

Cannabinoid production is a complex trait shaped by genetics (G) and environment (E), plus their interaction (G×E). Key influences include:

• Genotype: the plant’s genetic makeup determines which synthase genes are present and how strongly they’re expressed.
• Light: intensity and spectrum, especially UV-B, can increase cannabinoid and terpene production.
• Nutrients and water: stress from limited water or altered nutrient balance can shift metabolic priorities.
• Temperature: extremes can impair enzymatic activity, while ideal ranges support consistent biosynthesis.
• Harvest timing: cannabinoids accumulate and change over flower maturation; choosing the right harvest window affects potency and ratios.

Growers use genetic testing to predict chemotype and pair it with environmental controls to hit targets like high-THC or CBD-dominant flower. Intentional cultivation choices matter as much as genetic potential.

Beyond the plant: biotech approaches to cannabinoid manufacture

Plants aren’t the only route to cannabinoids anymore. Biotechnologists have engineered microbes and cell systems to produce cannabinoids in contained, scalable setups. Key techniques include:

• Yeast or bacterial production: inserting cannabis biosynthetic genes into Saccharomyces cerevisiae or other microbes lets fermentation produce CBGA, THC, CBD analogs, and rarer cannabinoids.
• Enzyme optimization: modifying synthase enzymes for higher activity or altered specificity expands the palette of accessible cannabinoids.
• CRISPR and gene editing: targeted edits in cannabis can dial up or down specific synthases, enabling new chemotype development without traditional crossing.

These methods can deliver consistent, pesticide-free cannabinoids at scale and enable synthesis of rare molecules that are difficult to extract from plant material. Regulatory frameworks still shape how biotech cannabinoids are deployed commercially.

How terpenes and minor cannabinoids interact with THC, CBD, and CBC

Cannabis chemistry is not limited to cannabinoids. Terpenes — volatile aromatic compounds — and minor cannabinoids (like CBG, CBN, THCV) combine with major cannabinoids to influence perceived effects and therapeutic profiles. Scientists study these interactions to understand the so-called “entourage effect,” where mixtures produce different outcomes than isolated molecules.

• Terpenes such as limonene, myrcene, and pinene modulate aroma and may influence absorption or receptor interaction.
• Minor cannabinoids like cannabigerol (CBG) can act as precursors or separate active compounds with distinct effects.
• Product formulation (whole-plant extract vs. isolate) changes how these chemicals work together.

Understanding these interactions helps clinicians and formulators design products for specific symptom relief, while consumers can choose strains based on more than just THC percentage.

Practical implications for growers, consumers, and clinicians

Knowing how cannabis makes its principal cannabinoids has practical value at several levels:

• Growers can select genetics and tweak environmental factors to produce targeted cannabinoid profiles and optimize yield.
• Processors choose decarboxylation, extraction, and refining techniques to deliver desired active compounds and purity.
• Researchers and clinicians use biosynthetic knowledge to explore novel cannabinoids for therapeutic use and to standardize dosing.
• Consumers gain insight into why two strains with similar THC percentages can feel very different based on minor cannabinoids and terpenes.

Advances in genetics, cultivation science, and biotechnology mean cannabinoid production is becoming more predictable and customizable. This opens pathways for new medicines and commercial products while raising questions about regulation, quality control, and accessibility.

You might also like:

• THCa strain Dark Rainbow: fruity flavor and potent high
• THCa vs THCp: differences, effects, potency and what to know
• THCa vape cart from Royal smells fresher than Pine-Sol
• Best cannabis flower: how to choose strains and effects that hit the spot
• Best cannabis vapes: sweet to stealthy and everything in between

William Anderson

William Anderson is a multimedia producer specializing in videos, podcasts, and interactive galleries. With five years of immersive content creation, he turns information into a rich audio‑visual experience. His storytelling skills draw you directly into the heart of every story, on any platform.